⚖️

CagriSema

Also known as: Cagrilintide + Semaglutide

Emerging ResearchWeight ManagementProvider Rx Required

How It Works

Fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Dual mechanism targets appetite, satiety, and gastric emptying through complementary pathways.

What It's Used For

Weight lossObesityType 2 diabetesMetabolic syndrome

Administration

Route: Subcutaneous injection

Typical Cycle: Ongoing with medical supervision

Safety & Side Effects

Possible Side Effects

⚠Nausea
⚠Vomiting
⚠Diarrhea
⚠Constipation
⚠Injection site reactions

Contraindications

✘Medullary thyroid carcinoma history
✘MEN2 syndrome
✘Pancreatitis
✘Pregnancy

Research Summary

Phase 3 REDEFINE trials showed ~22-25% body weight loss. Combination approach may offer superior weight loss to semaglutide alone with manageable side effect profile.

References

Frias JP et al. Lancet. 2023
Novo Nordisk REDEFINE program. 2024

Legal & Availability

Investigational — FDA submission pending

This peptide requires a prescription from a licensed provider.

Dosing Protocol

Standard: 2.4mg cagrilintide + 2.4mg semaglutide

Frequency: Once weekly

Timing: Any day, consistent schedule

Notes: Titrated up over 16 weeks

🔒

Unlock Full Dosing Protocol

Specific dosing, frequency, timing, cycling schedules, and stacking guidance are available with a BioRoot AI Pro subscription.

Stacks Well With

BPC-157

Injury repair, Gut healing

Full stacking protocols and cycling schedules available with Pro subscription.

Is CagriSema Right for You?

Our AI analyzes your symptoms, labs, and medical history to determine if this peptide fits your protocol — and at what dose.

Is CagriSema right for you?

Get a free personalized analysis based on your symptoms and goals — delivered to your inbox.

This information is for educational purposes only and is not medical advice. Do not use any peptide without consulting a qualified healthcare provider. BioRoot AI is a clinical decision support tool — not a medical provider.